You are here

  • Home
  • Archive
  • Volume 14, Issue 3
  • Fentanyl Pectin Nasal Spray reduces breakthrough cancer pain intensity compared with placebo in people taking at least 60 mg daily oral morphine or equivalent

Article Text

Article menu
Download PDFPDF
Pain management
Randomised controlled trial
Fentanyl Pectin Nasal Spray reduces breakthrough cancer pain intensity compared with placebo in people taking at least 60 mg daily oral morphine or equivalent

https://doi.org/10.1136/ebn1150

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests CPC is on the Advisory Board and Speakers Bureau for Meda Pharmaceuticals.